Axa S.A. Buys 9,597 Shares of Boston Scientific Co. (NYSE:BSX)

AXA S.A. increased its position in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 0.5% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,972,745 shares of the medical equipment provider's stock after buying an additional 9,597 shares during the period. AXA S.A. owned 0.13% of Boston Scientific worth $176,206,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in BSX. TFC Financial Management Inc. grew its stake in Boston Scientific by 308.8% in the fourth quarter. TFC Financial Management Inc. now owns 278 shares of the medical equipment provider's stock valued at $25,000 after acquiring an additional 210 shares during the period. West Oak Capital LLC bought a new position in Boston Scientific in the 4th quarter worth approximately $29,000. Valley National Advisers Inc. grew its holdings in Boston Scientific by 262.4% during the 4th quarter. Valley National Advisers Inc. now owns 395 shares of the medical equipment provider's stock valued at $35,000 after buying an additional 286 shares in the last quarter. Fairway Wealth LLC bought a new position in shares of Boston Scientific in the fourth quarter valued at approximately $36,000. Finally, Global Trust Asset Management LLC boosted its holdings in Boston Scientific by 64.5% in the 4th quarter. Global Trust Asset Management LLC now owns 436 shares of the medical equipment provider's stock valued at $39,000 after purchasing an additional 171 shares during the period. 89.07% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, CEO Michael F. Mahoney sold 164,443 shares of the stock in a transaction dated Thursday, May 1st. The stock was sold at an average price of $102.48, for a total value of $16,852,118.64. Following the transaction, the chief executive officer now owns 1,535,706 shares of the company's stock, valued at approximately $157,379,150.88. This represents a 9.67 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Vance R. Brown sold 4,826 shares of the company's stock in a transaction dated Monday, April 21st. The shares were sold at an average price of $95.09, for a total transaction of $458,904.34. Following the sale, the senior vice president now directly owns 36,193 shares of the company's stock, valued at $3,441,592.37. The trade was a 11.77 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 307,025 shares of company stock valued at $31,742,060. Corporate insiders own 0.50% of the company's stock.

Boston Scientific Stock Up 0.7 %

BSX traded up $0.69 on Wednesday, hitting $104.81. The company had a trading volume of 4,378,381 shares, compared to its average volume of 6,333,294. Boston Scientific Co. has a 52-week low of $71.88 and a 52-week high of $107.17. The stock has a fifty day simple moving average of $98.71 and a 200-day simple moving average of $95.66. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.08 and a quick ratio of 1.02. The firm has a market capitalization of $155.02 billion, a P/E ratio of 83.85, a P/E/G ratio of 2.79 and a beta of 0.68.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings data on Wednesday, April 23rd. The medical equipment provider reported $0.75 EPS for the quarter, beating the consensus estimate of $0.67 by $0.08. The business had revenue of $4.66 billion during the quarter, compared to analyst estimates of $4.57 billion. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. The company's revenue for the quarter was up 20.9% on a year-over-year basis. During the same quarter last year, the firm posted $0.56 earnings per share. As a group, equities analysts expect that Boston Scientific Co. will post 2.85 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have weighed in on the company. Needham & Company LLC raised their price target on Boston Scientific from $113.00 to $115.00 and gave the company a "buy" rating in a report on Thursday, April 24th. Robert W. Baird upped their target price on shares of Boston Scientific from $115.00 to $120.00 and gave the stock an "outperform" rating in a research report on Thursday, April 24th. BTIG Research reaffirmed a "buy" rating and set a $124.00 price target on shares of Boston Scientific in a research note on Wednesday, April 23rd. Stifel Nicolaus increased their price objective on Boston Scientific from $100.00 to $115.00 and gave the company a "buy" rating in a research report on Thursday, February 6th. Finally, Raymond James boosted their target price on Boston Scientific from $119.00 to $122.00 and gave the stock a "strong-buy" rating in a research report on Thursday, February 6th. Twenty-three investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $114.52.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.